(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Public ClinicalTrials.gov record NCT02039726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.
Study identification
- NCT ID
- NCT02039726
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 367 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2014 (Actual)
- Primary completion
- Feb 22, 2018 (Actual)
- Completion
- Sep 8, 2020 (Actual)
- Last update posted
- Feb 24, 2021
2014 – 2020
United States locations
- U.S. sites
- 36
- U.S. states
- 23
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| University of Southern California, Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| UC Davis Cancer Center | Sacramento | California | 95817 | — |
| Stanford University Medical Center Stanford Comprehensive Cancer Center | Stanford | California | 94305 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Emory Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60607 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Franciscan Alliance | Indianapolis | Indiana | 46237 | — |
| University of Kansas Medical Center Research Institute Inc | Westwood | Kansas | 66205 | — |
| LSU Health Sciences Center Feist Weiller Cancer Center | Shreveport | Louisiana | 71103 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| NY Medical College | Valhalla | New York | 10595 | — |
| UNC Linebreger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| Duke Cancer Institute at Duke University Health System | Durham | North Carolina | 27710 | — |
| Wake Forest University Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| University of Cincinnati | Cincinnati | Ohio | 45267 | — |
| Oregon Health and Science University Knight Cancer Institute | Portland | Oregon | 97239 | — |
| Geisinger Medical Center | Danville | Pennsylvania | 17822 | — |
| Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| University of Pennsylvania Health System | Philadelphia | Pennsylvania | 19104 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| MD Anderson Center, The University of Texas | Houston | Texas | 77030 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02039726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2021 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02039726 live on ClinicalTrials.gov.